Skip to content
drillr.ai
Sign up

BSX

BOSTON SCIENTIFIC CORP

NYSE · Healthcare · Medical - Devices · US

$45.05
+1.49%
Ask drillr

  • Oct 15, 2026, 23:00 UTC

    BOSTON SCIENTIFIC CORP shares closed at $44.14, up 2.65% from the prior trading day.

    Source:

  • Oct 12, 2026, 10:10 UTC

    Suzhou Party Secretary Fan Bo met BOSTON SCIENTIFIC CORP Global Chairman and CEO Han Ming Ma in Suzhou on October 12, 2026.

    Source:

  • Oct 9, 2026, 23:01 UTC

    BOSTON SCIENTIFIC CORP shares closed at $42.73, up 1.64% from the previous close.

    Source:

  • Oct 8, 2026, 23:16 UTC

    BOSTON SCIENTIFIC CORP shares rose 1.11% to $42.04, outperforming a declining market.

    Source:

  • Oct 7, 2026, 10:23 UTC

    Boston Scientific announced that Mark Bickel will become senior vice president, global accounting controller and chief accounting officer effective March 1, 2027, succeeding Emily Woodworth (Collins).

  • Oct 7, 2026, 10:23 UTC

    Boston Scientific announced that Emily Woodworth (Collins) will leave her role as senior vice president, global controller and chief accounting officer and become senior vice president, global finance controller and finance transformation effective March 1, 2027.

  • Oct 7, 2026, 10:23 UTC

    Boston Scientific announced that Joe Fitzgerald will become executive vice president and chief operating officer effective January 1, 2027, with a $1.05 million annual base salary, a bonus target of 110% of base salary, and a 2027 equity award valued at $7 million.

  • Oct 1, 2026, 20:45 UTC

    Boston Scientific released the full $8 million escrow holdback to Elutia in connection with Elutia's sale of its BioEnvelope business to Boston Scientific.

    Source:

  • Sep 24, 2026, 20:45 UTC

    Boston Scientific fully restored operations after a cyberattack that shut down its plants and distribution centers and likely caused lost orders, CEO Mike Mahoney said at an investor conference.

    Source:

  • Sep 23, 2026, 10:10 UTC

    Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific at Boston Scientific Corp, will retire effective January 1, 2027.

  • Sep 21, 2026, 11:46 UTC

    Zacks added AGCO, AEG and BSX to its Rank #5 (Strong Sell) list on September 21, 2026.

    Source:

  • Sep 16, 2026, 09:02 UTC

    AGCO, Boston Scientific (BSX), and Bath & Body Works (BBWI) were added to the Zacks Rank #5 (Strong Sell) List on September 16, 2026.

    Source:

  • Sep 11, 2026, 13:58 UTC

    Boston Scientific restored manufacturing and shipping after a cyberattack but warned it will likely miss its Q3 and full-year financial guidance.

    Source:

  • Sep 10, 2026, 15:31 UTC

    Boston Scientific restored key operations after a cyberattack, with products moving through its distribution network at or above normal levels as it works to fulfill customer orders and reduce backlogs.

    Source:

  • Sep 10, 2026, 12:39 UTC

    Boston Scientific is currently carrying out a major restructuring plan that is expected to bring certain financial benefits, according to an executive of the company.

    Source:

  • Sep 3, 2026, 23:59 UTC

    The FDA posted three Class 2 recall records for Boston Scientific's LUX-Dx heart monitor server software due to a flaw that can delay atrial fibrillation alerts.

    Source:

  • Aug 26, 2026, 14:58 UTC

    The U.S. Food and Drug Administration classified Boston Scientific's recall of its Enroute product as the most severe level.

    Source:

  • Aug 23, 2026, 08:32 UTC

    Callan Family Office LLC acquired a new position of 52,745 shares in Boston Scientific Corporation during the second quarter, valued at approximately $2,251,000.

    Source:

  • Aug 20, 2026, 07:16 UTC

    Aurora Investment Counsel disclosed a new position in Boston Scientific Corporation, purchasing 43,857 shares valued at approximately $1,872,000.

    Source:

  • Aug 19, 2026, 06:39 UTC

    Boston Scientific's next-generation prostate hyperplasia treatment device Rezūm EVO received approval from China's National Medical Products Administration, making China the first market globally to approve the product, which will be locally produced at Boston Scientific's Shanghai Lingang plant for the Chinese market.

    Source:

  • Aug 19, 2026, 02:59 UTC

    Boston Scientific's new-generation FARASTAR™ pulsed field ablation system for atrial fibrillation treatment, produced at its Shanghai Lingang plant, received approval from China's National Medical Products Administration.

    Source:

  • Aug 13, 2026, 07:36 UTC

    B. Riley Wealth Advisors Inc. reduced its stake in Boston Scientific Corporation by 56.1% during the quarter, selling 10,822 shares and retaining 8,467 shares, as disclosed in its SEC filing.

    Source:

  • Jul 30, 2026, 08:02 UTC

    Boston Scientific plans job cuts in Ireland.

    Source:

  • Jul 29, 2026, 10:30 UTC

    Boston Scientific Corporation reported net sales of $5.442 billion for the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis compared to the prior year period.

    Source:

  • Jul 27, 2026, 22:09 UTC

    Boston Scientific's board approved a new company-wide restructuring plan aimed at cutting costs and positioning the company for future growth, with expected job cuts.

    Source:

  • Jul 23, 2026, 19:57 UTC

    Boston Scientific recalled over 750,000 Faradrive Steerable Sheaths due to hemostatic valve damage risk, classified as a Class II recall by the FDA.

    Source:

  • Jun 8, 2026, 03:45 UTC

    Boston Scientific entered into an accelerated share repurchase agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock.

    Source: